Zomedica Announces Key Educational Presentations at Fetch dvm360 Veterinary Conference
Zomedica Corp. (NYSE American:ZOM) has announced its sponsorship of educational programs at the upcoming Fetch dvm360 Veterinary Conference in Kansas City, MO, from August 23-25, 2024. The company will showcase its TRUFORMA® Bulk Acoustic Wave diagnostic platform, PulseVet® shock wave platform, and VETGuardian® zero-touch remote monitor at Booth #409. Zomedica is sponsoring presentations by leading veterinary experts, including topics on periodontal therapy, dermatology, orthopedic injuries, postoperative care, and gastrointestinal diagnostics. This partnership with Fetch dvm360 aims to further the advancement of veterinary practice and patient care through education and innovative solutions.
Zomedica Corp. (NYSE American:ZOM) ha annunciato il suo patrocinio di programmi educativi alla prossima Fetch dvm360 Veterinary Conference che si terrà a Kansas City, MO, dal 23 al 25 agosto 2024. L'azienda presenterà la sua piattaforma diagnostica TRUFORMA® Bulk Acoustic Wave, la piattaforma di onde d'urto PulseVet® e il monitor remoto VETGuardian® a contatto zero allo Stand #409. Zomedica sponsorizza presentazioni di esperti veterinari di spicco, trattando temi come la terapia parodontale, la dermatologia, le lesioni ortopediche, la cura post-operatoria e le diagnosi gastrointestinali. Questa collaborazione con Fetch dvm360 punta a promuovere l'avanzamento della pratica veterinaria e della cura dei pazienti attraverso l'istruzione e soluzioni innovative.
Zomedica Corp. (NYSE American:ZOM) ha anunciado su patrocinio de programas educativos en la próxima Fetch dvm360 Veterinary Conference que se llevará a cabo en Kansas City, MO, del 23 al 25 de agosto de 2024. La compañía mostrará su plataforma de diagnóstico TRUFORMA® Bulk Acoustic Wave, la plataforma de ondas de choque PulseVet® y el monitor remoto sin contacto VETGuardian® en el stand #409. Zomedica está patrocinando presentaciones de destacados expertos veterinarios, que incluyen temas sobre terapia periodontal, dermatología, lesiones ortopédicas, atención postoperatoria y diagnósticos gastrointestinales. Esta asociación con Fetch dvm360 tiene como objetivo avanzar en la práctica veterinaria y la atención al paciente a través de la educación y soluciones innovadoras.
Zomedica Corp. (NYSE American:ZOM)는 2024년 8월 23일부터 25일까지 미주리주 캔자스시티에서 열리는 Fetch dvm360 Veterinary Conference에서 교육 프로그램을 후원한다고 발표했습니다. 회사는 TRUFORMA® 벌크 음향파 진단 플랫폼, PulseVet® 충격파 플랫폼, VETGuardian® 제로 터치 원격 모니터를 부스 #409에서 선보일 예정입니다. Zomedica는 치주 치료, 피부과, 정형외과 부상, 수술 후 관리 및 위장 진단과 같은 주제를 다루는 저명한 수의학 전문가들의 발표를 후원합니다. Fetch dvm360과의 이 파트너십은 교육과 혁신적인 솔루션을 통해 수의학 실습과 환자 치료의 발전을 목표로 하고 있습니다.
Zomedica Corp. (NYSE American:ZOM) a annoncé son parrainage de programmes éducatifs lors de la prochaine Fetch dvm360 Veterinary Conference qui se déroulera à Kansas City, MO, du 23 au 25 août 2024. La société présentera sa plateforme de diagnostic TRUFORMA® Bulk Acoustic Wave, la plateforme d'ondes de choc PulseVet® et le moniteur sans contact VETGuardian® au stand n°409. Zomedica parraine les présentations de vétérinaires de premier plan, abordant des sujets tels que la thérapie parodontale, la dermatologie, les blessures orthopédiques, les soins postopératoires et les diagnostics gastro-intestinaux. Ce partenariat avec Fetch dvm360 vise à faire progresser la pratique vétérinaire et les soins aux patients grâce à l'éducation et à des solutions innovantes.
Zomedica Corp. (NYSE American:ZOM) hat sein Sponsoring von Bildungsprogrammen auf der bevorstehenden Fetch dvm360 Veterinärkonferenz, die vom 23. bis 25. August 2024 in Kansas City, MO, stattfinden wird, bekannt gegeben. Das Unternehmen wird seine TRUFORMA® Bulk Acoustic Wave-Diagnoseplattform, die PulseVet®-Stoßwellenplattform und den VETGuardian®-Berührungslosen Fernmonitor am Stand #409 präsentieren. Zomedica sponsort Präsentationen führender veterinärmedizinischer Experten, darunter Themen zu parodontalen Therapien, Dermatologie, orthopädischen Verletzungen, postoperativer Versorgung und gastrointestinaler Diagnostik. Diese Partnerschaft mit Fetch dvm360 zielt darauf ab, die Weiterentwicklung der veterinärmedizinischen Praxis und der Patientenversorgung durch Bildung und innovative Lösungen voranzutreiben.
- Sponsorship of educational programs at a major veterinary conference, enhancing brand visibility
- Showcasing multiple innovative veterinary products at the conference
- Expansion of product applications and entry into global markets
- None.
Leading veterinary experts to present at the Fetch dvm360 Veterinary Conference in Kansas City, August 23-25, 2024
ANN ARBOR, MI / ACCESSWIRE / August 20, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced its sponsorship of educational programs at the upcoming Fetch dvm360 Veterinary Conference, taking place in Kansas City, MO, from August 23-25, 2024.
"We are proud to continue our partnership with the Fetch dvm360 series of veterinary Continuing Education programs," commented Nicole Westfall, Zomedica's Senior Vice President of Marketing. "The Kansas City conference provides an exceptional platform for education, featuring some of the most respected experts in veterinary medicine. We are honored to sponsor presentations by distinguished speakers who will share their invaluable knowledge and insights, furthering the advancement of veterinary practice and patient care."
Kevin Klass, Zomedica's Senior Vice President of Sales, added, "Our TRUFORMA® Bulk Acoustic Wave diagnostic platform, PulseVet® shock wave platform, and the VETGuardian® zero-touch remote monitor have made significant strides, expanding into global markets and introducing innovative applications. The Fetch dvm360 conference in Kansas City provides an excellent opportunity for us to showcase the capabilities of these systems. We look forward to connecting with professionals eager to enhance patient care and practice efficiency through our cutting-edge diagnostic and therapeutic solutions."
Zomedica will be exhibiting at Booth #409 during the Fetch Kansas City Conference.
The Company is sponsoring the following presentations by leading experts in veterinary medicine:
Heidi Lobprise, DVM, DAVDC presents "Step Up to Optimal Periodontal Therapy" on Friday, August 23rd from 11:00am - 12:00pm
Ashley Bourgeois, DVM, DACVD presents "Digital Derm: How to Implement Cytology in Your Busy Practice" on Saturday, August 24th from 9:15am - 10:15am
David Dycus, DVM, MS, CCRP, DACVS-SA presents "My Patient Has A Front Limb Lameness - Now What? Soft Tissue Orthopedic Injuries" on Saturday, August 24th from 1:30pm - 2:30pm
Courtney Campbell, DVM, DACVS-SA presents "Beyond Surgery: Conventional Untapped Remedies for Maximizing Postoperative Success" on Saturday, August 24th from 2:45pm - 3:45pm
Gary Oswald, DVM, MS, DACVIM (Int Med) presents "Have the 'Guts' to Run These Tests? Gastrointestinal Blood Panels" on Saturday, August 24th from 4:30pm - 5:30 pm
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the expected market and Zomedica's share of such market, continued growth of sales, the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work including the development of new cartridges; uncertainty as to the timing and results of verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products, particularly in the Middle East, Africa and India; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com
FAQ
What products will Zomedica (ZOM) showcase at the Fetch dvm360 Veterinary Conference in August 2024?
When and where is the Fetch dvm360 Veterinary Conference that Zomedica (ZOM) is sponsoring in 2024?
What topics will be covered in the Zomedica (ZOM) sponsored presentations at the Fetch dvm360 Conference in August 2024?
Where can attendees find Zomedica's (ZOM) booth at the Fetch dvm360 Veterinary Conference in Kansas City?
